Search

Your search keyword '"Quiroga, Dionisia"' showing total 161 results
Start Over Author "Quiroga, Dionisia"
161 results on '"Quiroga, Dionisia"'

3. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample

Author

Krishan, Satyam, Asad, Zain Ul Abideen, Quiroga, Dionisia, Ghazi, Sanam M., Quartermaine, Cooper, Braunstein, Zachary, Kola-Kehinde, Onaopepo, Shaaban, Adnan, Habib, Alma, Khan, Sarah, Cheng, Richard, Brammer, Jonathan E., and Addison, Daniel

Published
2024
Full Text
View/download PDF

4. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer

Author

Johnson, Kai C. C., Ni, Ai, Quiroga, Dionisia, Pariser, Ashley C., Sudheendra, Preeti K., Williams, Nicole O., Sardesai, Sagar D., Cherian, Mathew, Stover, Daniel G., Gatti-Mays, Margaret, Ramaswamy, Bhuvaneswari, Lustberg, Maryam, Jhawar, Sachin, Skoracki, Roman, and Wesolowski, Robert

Published
2024
Full Text
View/download PDF

6. The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Author

Johnson, Kai Conrad Cecil, Goldstein, Daniel, Tharakan, Jasmin, Quiroga, Dionisia, Kassem, Mahmoud, Grimm, Michael, Miah, Abdul, Vargo, Craig, Berger, Michael, Sudheendra, Preeti, Pariser, Ashley, Gatti-Mays, Margaret E., Williams, Nicole, Stover, Daniel, Sardesai, Sagar, Wesolowski, Robert, Ramaswamy, Bhuvaneswari, Tozbikian, Gary, Schnell, Patrick M., and Cherian, Mathew A.

Published
2023
Full Text
View/download PDF

9. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer

Author

Sukumar, Jasmine S., Quiroga, Dionisia, Kassem, Mahmoud, Grimm, Michael, Shinde, Namrata Vilas, Appiah, Leslie, Palettas, Marilly, Stephens, Julie, Gatti-Mays, Margaret E., Pariser, Ashley, Cherian, Mathew, Stover, Daniel G., Williams, Nicole, Van Deusen, Jeffrey, Wesolowski, Robert, Lustberg, Maryam, Ramaswamy, Bhuvaneswari, and Sardesai, Sagar

Published
2021
Full Text
View/download PDF

12. Supplementary Figure 8 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

13. Supplementary Table 2 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

14. Supplementary Figure 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure 2 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

16. Supplementary Figure 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

18. Supplementary Table 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure 4 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

20. Data from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Table 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

22. Supplementary Table 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

23. Supplementary Figure 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

24. Supplementary Figure 7 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

25. Supplementary Table 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

26. Supplementary Table 4 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

27. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.

Author

Sukumar, Jasmine S., Sardesai, Sagar, Ni, Andy, Williams, Nicole, Johnson, Kai, Quiroga, Dionisia, Ramaswamy, Bhuvana, Wesolowski, Robert, Cherian, Mathew, Stover, Daniel G., Gatti‐Mays, Margaret, Pariser, Ashley, Sudheendra, Preeti, George, Mridula A., and Lustberg, Maryam

Subjects
HORMONE therapy, EPIDERMAL growth factor receptors, BREAST cancer, HORMONE receptors, CLINICAL indications
Abstract

Background: The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit and clinical indications of ovarian suppression (OS) is poorly elucidated. We described real‐world patterns surrounding choice of ET and clinicopathologic features which predicted treatment with OS in a contemporary cohort of premenopausal women with HR+/HER2+ BC. Methods: This retrospective analysis included premenopausal patients with nonmetastatic HR+/HER2+ BC from the CancerLinQ Discovery database from January 2010 to May 2020. Women were less than 50 years and received chemotherapy, anti‐HER2 therapy, and ET. They were categorized into 1 of 4 groups based on type of ET prescribed at initiation: aromatase inhibitor (AI) + OS, OS, tamoxifen + OS, or tamoxifen. Multivariable logistic regression assessed associations between clinicopathologic features and OS use. Results: Out of 360,540 patients with BC, 937 were included. The majority (n = 818, 87%) were prescribed tamoxifen, whereas 4 (0.4%), 50 (5.3%), and 65 (6.9%) received OS, tamoxifen + OS and AI + OS, respectively. No clinicopathologic features predicted OS use apart from age; patients <35 years were more likely to receive OS compared with those ≥35 years (odds ratio 2.33, p < 0.001). Conclusions: This is the first real‐world study evaluating ET treatment patterns in HR+/HER2+ premenopausal BC. OS use was uncommon and the majority received tamoxifen as the preferred ET regardless of most clinicopathologic risk factors. Additional research is needed to optimize ET decisions in young women with this distinct BC subtype. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton’s Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, additional, Jeon, Hyeongseon, additional, Li, Jianying, additional, Quiroga, Dionisia, additional, Schwarz, Emily, additional, Wu, Richard C., additional, Zelinskas, Sara, additional, Lapurga, Gabriella, additional, Abreo, Alexander, additional, Stiff, Andrew, additional, Shaffer, Jami, additional, Blaser, Bradley W., additional, Old, Matthew, additional, Wesolowski, Robert, additional, Xin, Gang, additional, Kendra, Kari L., additional, Chung, Dongjun, additional, and Carson, William E., additional

Published
2023
Full Text
View/download PDF

33. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

Author

Wesolowski, Robert, Stiff, Andrew, Quiroga, Dionisia, McQuinn, Christopher, Li, Zaibo, Nitta, Hiroaki, Savardekar, Himanshu, Benner, Brooke, Ramaswamy, Bhuvaneswari, Lustberg, Maryam, Layman, Rachel M., Macrae, Erin, Kassem, Mahmoud, Williams, Nicole, Sardesai, Sagar, VanDeusen, Jeffrey, Stover, Daniel, Cherian, Mathew, Mace, Thomas A., Yu, Lianbo, Duggan, Megan, and Carson, III, William E.

Published
2020
Full Text
View/download PDF

34. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.

Author

Williams, Nicole O., Quiroga, Dionisia, Johnson, Courtney, Brufsky, Adam, Chambers, Mara, Bhattacharya, Saveri, Patterson, Maria, Sardesai, Sagar D., Stover, Daniel, Lustberg, Maryam, Noonan, Anne M., Cherian, Mathew, Bystry, Darlene M., Hill, Kasey L., Chen, Min, Phelps, Mitch A., Grever, Michael, Stephens, Julie A., Ramaswamy, Bhuvaneswari, and Carson III, William E.

Abstract

Background: Heat shock protein 90 (HSP90) is a molecular chaperone required for stabilization of client proteins over-activated in triple-negative breast cancer (TNBC). Over-expression of HSP90 client proteins has been implicated in paclitaxel resistance. Onalespib (AT13387) is a potent inhibitor of HSP90 that could improve paclitaxel efficacy when administered in combination. Design: This phase Ib trial administered onalespib with paclitaxel in patients with advanced TNBC to assess safety and establish a recommended phase II dose (RP2D). Objectives: The primary objectives were determining the dose-limiting toxicities and maximum tolerated dose of combination therapy. Secondary objectives included pharmacokinetic (PK) analysis and determination of overall response rate (ORR), duration of response (DOR), and progression-free survival (PFS). Methods: Patients with advanced TNBC were treated with standard dose intravenous paclitaxel in combination with intravenous onalespib at doses ranging from 120 to 260 mg/m2 administered on days 1, 8, and 15 of a 28-day cycle using a standard 3 + 3 design. A total of 15 patients were enrolled to dose expansion cohort at RP2D to confirm safety profile. Results: Thirty-one patients were enrolled in the study, of which over 90% had received prior taxane therapy. Paclitaxel was given for metastatic disease in 23% of patients. Adverse events (AEs) included anemia (grade 3: 20%), lymphopenia (grade 3: 17%), and neutropenia (grade 3: 33%, grade 4: 4%). The most frequent grade ⩾3 non-hematologic AE was diarrhea (7%). The established RP2D was 260 mg/m2 onalespib when given with paclitaxel at 80 mg/m2. PK analysis revealed a modest drug interaction profile for onalespib in the combination regimen. ORR was 20%. Three patients achieved complete responses, all of whom had received prior taxane therapy. Median DOR was 5.6 months; median PFS was 2.9 months. Conclusion: Combination treatment with onalespib and paclitaxel had an acceptable toxicity profile and RP2D was determined to be 260 mg/m2 of onalespib. Combination therapy showed antitumor activity in patients with advanced TNBC. Trial registration: Onalespib and paclitaxel in treating patients with advanced TNBC https://clinicaltrials.gov/ct2/show/NCT02474173. Plain language summary: Phase 1b study of HSP90 inhibitor called onalespib in combination with paclitaxel in patients with advanced triple-negative breast cancer This Phase 1b study demonstrated that treatment with a combination of onalespib and paclitaxel was reasonably well tolerated by most patients. Onalespib at 260 mg/m2 given intravenously on days 1, 8 and 15 on 28-day cycles in combination with standard dose and schedule of paclitaxel was established as the recommended phase 2 dose for further clinical development. Despite minor drug-drug interactions between these 2 agents, onalespib did not alter paclitaxel exposure and paclitaxel did not affect exposure to onalespib. While onalespib with paclitaxel combination therapy did not yield durable objective responses or prolonged progression-free survival, there were several patients with long-lasting benefit from this combination including patients who previously experienced progression on taxane therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Abstract P4-02-17: Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in early-stage HER2-negative breast cancer: a US National Cancer Database analysis

Author

Quiroga, Dionisia, primary, Grimm, Michael, additional, Stephens, Julie, additional, Johnson, Kai, additional, Williams, Nicole, additional, Sudheendra, Preeti K., additional, Cherian, Mathew A., additional, Stover, Daniel, additional, Pariser, Ashley C., additional, Gatti-Mays, Margaret, additional, Wesolowski, Robert, additional, Bazan, Jose G., additional, Beyer, Sasha, additional, Park, Ko Un, additional, Oppong, Bridget, additional, Ramaswamy, Bhuvaneswari, additional, White, Julia, additional, Jhawar, Sachin R., additional, and Sardesai, Sagar, additional

Published
2023
Full Text
View/download PDF

41. CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer

Author

Quiroga, Dionisia Marie, primary, Pinette, Ashley, additional, Benner, Brooke, additional, Schwarz, Emily, additional, Wesolowski, Robert, additional, Stiff, Andrew, additional, Zelinskas, Sara, additional, Macrae, Erin, additional, Lustberg, Maryam, additional, Mrozek, Ewa, additional, Ramaswamy, Bhuvaneswari, additional, and Carson, William E, additional

Published
2022
Full Text
View/download PDF

44. 687 MDSC gene expression analysis in patients with cancer and the response to inhibition of Bruton's tyrosine kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, additional, Quiroga, Dionisia, additional, Chung, Donjun, additional, Schwarz, Emily, additional, Lapurga, Gabriella, additional, Shaffer, Jami, additional, Blaser, Bradley, additional, Old, Matthew, additional, Wesolowski, Robert, additional, Kendra, Kari, additional, and Carson, William, additional

Published
2021
Full Text
View/download PDF

46. Association of pathological complete response rates and TILs in triple-negative breast cancer patients.

Author

Kassem, Mahmoud, primary, Goldstein, Daniel, additional, Schnell, Patrick, additional, Grimm, Michael, additional, Quiroga, Dionisia Marie, additional, Miah, Abdul, additional, Vargo, Craig, additional, Shinde, Namrata Vilas, additional, Michael, Berger, additional, Pariser, Ashley, additional, Gatti-Mays, Margaret Elena, additional, VanDeusen, Jeffrey Bryan, additional, Williams, Nicole Olivia, additional, Stover, Daniel G., additional, Sardesai, Sagar D., additional, Wesolowski, Robert, additional, Lustberg, Maryam B., additional, Ramaswamy, Bhuvaneswari, additional, Tozbikian, Gary, additional, and Cherian, Mathew Amprayil, additional

Published
2021
Full Text
View/download PDF

47. BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer

Author

Sukumar, Jasmine Singh, primary, Quiroga, Dionisia, additional, Kassem, Mahmoud, additional, Grimm, Michael, additional, Shinde, Namrata Vilas, additional, Appiah, Leslie, additional, Palettas, Marilly, additional, Stephens, Julie, additional, Cherian, Mathew, additional, Stover, Daniel, additional, Williams, Nicole, additional, Van Deusen, Jeffrey, additional, Wesolowski, Robert, additional, Lustberg, Maryam, additional, Ramaswamy, Bhuvaneswari, additional, and Sardesai, Sagar, additional

Published
2021
Full Text
View/download PDF

48. Abstract PS13-46: Immunomodulation with dexamethasone in neoadjuvant chemotherapy for triple negative breast cancer

Author

Goldstein, Daniel, primary, Kassem, Mahmoud, additional, Quiroga, Dionisia, additional, Miah, Abdul, additional, Vargo, Craig, additional, Shinde, Namrata Vilas, additional, Berger, Michael, additional, Williams, Nicole, additional, Stover, Daniel, additional, Sardesai, Sagar, additional, Lustberg, Maryam, additional, Ramaswamy, Bhuvaneswari, additional, Tozbikian, Gary, additional, Schnell, Patrick, additional, and Cherian, Mathew, additional

Published
2021
Full Text
View/download PDF

50. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development

Author

Benner,Brooke, Good,Logan, Quiroga,Dionisia, Schultz,Thomas E, Kassem,Mahmoud, Carson,William E, Cherian,Mathew A, Sardesai,Sagar, and Wesolowski,Robert

Subjects
Drug Design, Development and Therapy
Abstract

Brooke Benner,1,* Logan Good,1,* Dionisia Quiroga,2 Thomas E Schultz,3 Mahmoud Kassem,2 William E Carson,1 Mathew A Cherian,2 Sagar Sardesai,2 Robert Wesolowski2 1Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; 2Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; 3Department of Pharmacy, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA*These authors contributed equally to this workCorrespondence: Robert WesolowskiDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 1250 Lincoln Tower, Columbus, OH 43210 Tel +1 614 366 5125Fax +1 614 293 7264Email Robert.Wesolowski@osumc.eduAbstract: Tenosynovial giant cell tumor (TGCT) is a rare benign tumor that involves the synovium, bursa, and tendon sheath, resulting in reduced mobility of the affected joint or limb. The current standard of care for TGCT is surgical resection. However, some patients have tumor recurrence, present with unresectable tumors, or have tumors that are in locations where resection could result in amputations or significant debility. Therefore, the development of systemic agents with activity against TGCT to expand treatment options is a highly unmet medical need. Pathologically, TGCT is characterized by the overexpression of colony-stimulating factor 1 (CSF-1), which leads to the recruitment of colony-stimulating factor-1 receptor (CSF-1R) expressing macrophages that make up the primary cell type within these giant cell tumors. The binding of CSF-1 and CSF-1R controls cell survival and proliferation of monocytes and the switch from a monocytic to macrophage phenotype contributing to the growth and inflammation within these tumors. Therefore, molecules that target CSF-1/CSF-1R have emerged as potential systemic agents for the treatment of TGCT. Given the role of macrophages in regulating tumorigenesis, CSF1/CSF1R-targeting agents have emerged as attractive therapeutic targets for solid tumors. Pexidartinib is an orally bioavailable and potent inhibitor of CSF-1R which is one of the most clinically used agents. In this review, we discuss the biology of TGCT and review the pre-clinical and clinical development of pexidartinib which ultimately led to the FDA approval of this agent for the treatment of TGCT as well as ongoing clinical studies utilizing pexidartinib in the setting of cancer.Keywords: pexidartinib, colony-stimulating factor 1 receptor, tenosynovial giant cell tumors, pigmented villonodular synovitis

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results